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EDITORIAL
Podocytes as a target for treatment with ACE inhibitors
and/or angiotensin-receptor blockers
Angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II (Ang II) receptor blockers have wide-
ranging beneficial effects on proteinuria and progres-
sion in all kinds of chronic renal disease [1–3]. These
effects are based on two mechanisms. First, on the
lowering of blood pressure, including specific effects
on pre- and postglomerular arterioles followed by de-
creasing glomerular capillary pressure, and second, on
pressure- independent mechanisms that are not well un-
derstood [4–6]. The study from Durvasula et al [7] in the
present issue of Kidney International addresses aspects
of the question of how podocytes are involved in these
mechanisms.
It is generally accepted that high glomerular pressure
is deleterious to the glomerulus, and that the podocyte
is the cell which is primarily concerned. Podocytes are a
specific type of pericyte which are suggested to counter-
act the pressure-dependent elastic distention of glomeru-
lar capillaries. Failure in this function—in the case of
pressure that is too high—leads to capillary dilation, a
situation well known to precede the development of seg-
mental glomerulosclerosis [8]. The underlying assump-
tion to this understanding is that podocytes respond to
increased transmural pressure gradients by increas-
ing their counteracting tonus. Previous studies have
indeed shown that podocytes are mechanosensitive,
responding in vitro to mechanical stress by rearrange-
ment of their actin cytoskeleton [9]. Why and how
a podocyte fails when the pressure rises is poorly
understood.
To simulate high pressure conditions in vitro, the
authors exposed cultured podocytes to cyclic stretch. As
suggested from previous studies that podocytes are part
of a local renin-angiotensin system (RAS) [10, 11], the
authors show that a primary culture system of mouse
podocytes was able to produce Ang II (suggesting that
the cells produced and secreted renin that finally was
turned into Ang II) and—shown in a culture system with
immortalized mouse podocytes—that theses podocytes
(as was repeatedly shown for podocytes in situ) express
angiotensin II type 1 (AT1) receptors. Actually, the au-
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thors showed that exposing cultured podocytes to cyclic
stretch increases both the production of Ang II as well
as the expression of AT1 surface receptors. The latter
observation was confirmed and extended to the in vivo
situation by immunocytochemical studies showing that
podocytes in the 5/6 nephrectomy model in the rat ex-
press increased amounts of this receptor protein. This
suggests that the response of podocytes to increased dis-
tension by increasing its tonus is mediated via AT1 signal-
ing, consistent with AT1-mediated contractile responses
to Ang II at many other sites in the body. Thus, Ang II
blockade in chronic renal disease (CRD) might become
effective at two sites (i.e., at arterioles in general [lower-
ing glomerular capillary pressure], and second, directly at
the podocyte), probably resulting in three effects: lower-
ing podocyte tonus, decreasing the rate of apoptosis, and
decreasing protein leakage.
In the present study by Durvasula et al [7], the main
emphasis was on apoptosis. The idea that apoptotic cell
loss may lead to a decrease in podocyte density and con-
tribute to progression of CRD has previously been raised
[12], and evidence has been presented that transform-
ing growth factor (TGF) signaling might be crucially in-
volved. In the present study, it is shown that mechanical
challenge increases the rate of apoptosis. Moreover, it
is shown that this increase can be blunted (at least par-
tially) by treatment with unspecific or AT1-specific Ang II
receptor blockers, demonstrating that apoptosis is stim-
ulated via AT1 signaling. Blocking this signaling path-
way on a long-term basis, followed by decreasing the rate
of podocyte apoptosis, might well account for decelerat-
ing progression of CRD generally seen along with such
treatment.
A third beneficial effect of Ang II blockade on progres-
sion concerns proteinuria, or, better said, protein leakage
through the glomerular filter. Ang II infusion has been
shown to induce proteinuria independent of any pressure
effects [13], and there are, meanwhile, many studies which
show that proteinuria/protein leakage is ameliorated by
Ang II blockade, in addition to the effects derived from
lowering blood pressure (see above). These effects are
most probably mediated in the podocyte; it was clearly
shown that they interfere with the distribution of pro-
teins (ZO1, nephrin) relevant for the barrier function of
the slit diaphragm [4, 6]. For instance, ACE inhibitors re-
store a normal distribution pattern of ZO1 in proteinuric
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Munic Wistar Froemters (MWF) rats accompanied by
a decrease in proteinuria [4]. If we combine these find-
ings with the results of the present study by Durvasula
et al [7], suggesting that increasing the tonus of podocytes
is achieved via AT1 signaling, we come to the conclu-
sion that both functions of podocytes—counteracting
pressure and maintaining a size-restrictive barrier—are
likely to be intimately related to the cytoskeletal func-
tions of the podocyte. Thus, increasing the tonus of
podocytes in response to increasing pressure gradients
(a favorable function) obviously interferes with the bar-
rier function of podocytes, resulting in increased protein
leakage. Thus, counteracting pressure and keeping up the
barrier for macromolecules might actually represent a
boat trip between Skylla and Charybdis. Too much tonus
will lead to loss of the size-restrictive barrier; maintain-
ing the barrier is only possible at a moderate tonus, run-
ning the danger of capillary dilation at increased capillary
pressure.
The problem arising from combining selective leaki-
ness with stability in the glomerulus has already been
discussed in the past, at a time when we knew noth-
ing about the molecular organization of the slit mem-
brane and its connections to the cytoskeleton. The study
by Durvasula et al [7] showing that the podocyte rep-
resents a local RAS reopens the discussion on the
interrelationships between hydraulic permeability, size
restrictive barrier, and stability of the glomerular filter. It
appears that the local RAS is a main regulator of these
interrelationships.
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